{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:30:59Z","timestamp":1793467859400,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2023-C-003"],"award-info":[{"award-number":["CSH-2023-C-003"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2024-C-002"],"award-info":[{"award-number":["CSH-2024-C-002"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2025-C-003"],"award-info":[{"award-number":["CSH-2025-C-003"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University, Taiwan","doi-asserted-by":"publisher","award":["CMU114-ASIA-15"],"award-info":[{"award-number":["CMU114-ASIA-15"]}],"id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chung Shan Medical University","id":[{"id":"https:\/\/ror.org\/059ryjv25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40261-026-01594-4","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:25:23Z","timestamp":1789219523000},"page":"1267-1278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-Dependent Association of Long-Term Metformin Use and Diabetic Nephropathy Risk in Patients with Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Taiwan"],"prefix":"10.1007","volume":"46","author":[{"given":"Kuang-Hua","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Yan","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Han","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-4645","authenticated-orcid":false,"given":"Chien-Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"1594_CR1","volume-title":"StatPearls [Internet]","author":"P Rout","year":"2026","unstructured":"Rout P, Jialal I. Diabetic nephropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"1594_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","volume":"2067","author":"MK Sagoo","year":"2020","unstructured":"Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3\u20137.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"1594_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00592-019-01324-7","volume":"56","author":"J Wang","year":"2019","unstructured":"Wang J, Han Q, Zhao L, Zhang J, Wang Y, Wu Y, et al. Identification of clinical predictors of diabetic nephropathy and non-diabetic renal disease in Chinese patients with type 2 diabetes, with reference to disease course and outcome. Acta Diabetol. 2019;56(8):939\u201346.","journal-title":"Acta Diabetol"},{"issue":"12","key":"1594_CR4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"1594_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14007","volume":"22","author":"NM Selby","year":"2020","unstructured":"Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(Suppl 1):3\u201315.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1594_CR6","first-page":"1059","volume":"31","author":"D Kawanami","year":"2016","unstructured":"Kawanami D, Matoba K, Utsunomiya K. Signaling pathways in diabetic nephropathy. Histol Histopathol. 2016;31(10):1059\u201367.","journal-title":"Histol Histopathol"},{"issue":"7","key":"1594_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072632","volume":"21","author":"L Opazo-Rios","year":"2020","unstructured":"Opazo-Rios L, Mas S, Marin-Royo G, Mezzano S, Gomez-Guerrero C, Moreno JA, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7):2632.","journal-title":"Int J Mol Sci"},{"key":"1594_CR8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.12688\/f1000research.7693.1","volume":"5","author":"SC Tang","year":"2016","unstructured":"Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res. 2016;5:1044.","journal-title":"F1000Res"},{"key":"1594_CR9","doi-asserted-by":"crossref","unstructured":"American Diabetes A. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S135-S51.","DOI":"10.2337\/dc20-S011"},{"issue":"12","key":"1594_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1055\/s-0032-1321878","volume":"44","author":"Y Ishibashi","year":"2012","unstructured":"Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res. 2012;44(12):891\u20135.","journal-title":"Horm Metab Res"},{"issue":"1","key":"1594_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-023-00595-3","volume":"9","author":"Z Cai","year":"2023","unstructured":"Cai Z, Wu X, Song Z, Sun S, Su Y, Wang T, et al. Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis. Cell Discov. 2023;9(1):104.","journal-title":"Cell Discov"},{"key":"1594_CR12","doi-asserted-by":"crossref","unstructured":"Amador-Licona N, Guizar-Mendoza J, Vargas E, Sanchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000 Nov-Dec;31(6):571-5.","DOI":"10.1016\/S0188-4409(00)00241-1"},{"issue":"11","key":"1594_CR13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/jcph.1452","volume":"59","author":"MC Lee","year":"2019","unstructured":"Lee MC, Lee CH, Chang LY, Chang CH, Zhang JF, Lee MR, et al. Association of metformin use with end-stage renal disease in patients with type 2 diabetes mellitus: a nationwide cohort study under the pay-for-performance program. J Clin Pharmacol. 2019;59(11):1443\u201352.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1594_CR14","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.18632\/oncotarget.23387","volume":"9","author":"WH Hsu","year":"2018","unstructured":"Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY, Shin SJ. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget. 2018;9(4):5416\u201323.","journal-title":"Oncotarget"},{"issue":"2","key":"1594_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37796\/2211-8039.1013","volume":"10","author":"SW Lai","year":"2020","unstructured":"Lai SW, Liao KF, Lin CL, Lin CC, Lin CH. Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013. Biomedicine (Taipei). 2020;10(2):1\u20134.","journal-title":"Biomedicine (Taipei)."},{"key":"1594_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"issue":"8","key":"1594_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00228-011-1014-7","volume":"67","author":"T Grimmsmann","year":"2011","unstructured":"Grimmsmann T, Himmel W. Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? Eur J Clin Pharmacol. 2011;67(8):847\u201354.","journal-title":"Eur J Clin Pharmacol"},{"key":"1594_CR18","doi-asserted-by":"crossref","unstructured":"Wellington K. Rosiglitazone\/Metformin. Drugs. 2005;65(11):1581-92; discussion 93-4.","DOI":"10.2165\/00003495-200565110-00013"},{"issue":"2","key":"1594_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11606-017-4219-3","volume":"33","author":"ZA Marcum","year":"2018","unstructured":"Marcum ZA, Forsberg CW, Moore KP, de Boer IH, Smith NL, Boyko EJ, et al. Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease. J Gen Intern Med. 2018;33(2):155\u201365.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"1594_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124239","volume":"21","author":"D Kawanami","year":"2020","unstructured":"Kawanami D, Takashi Y, Tanabe M. Significance of metformin use in diabetic kidney disease. Int J Mol Sci. 2020;21(12):4239.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1594_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1365-2796.2004.01420.x","volume":"257","author":"J De Jager","year":"2005","unstructured":"De Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005;257(1):100\u20139.","journal-title":"J Intern Med"},{"issue":"1","key":"1594_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/joim.12128","volume":"275","author":"J de Jager","year":"2014","unstructured":"de Jager J, Kooy A, Schalkwijk C, van der Kolk J, Lehert P, Bets D, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275(1):59\u201370.","journal-title":"J Intern Med"},{"issue":"12","key":"1594_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/dom.12764","volume":"18","author":"N Carlson","year":"2016","unstructured":"Carlson N, Hommel K, Olesen JB, Gerds TA, Soja AM, Vilsboll T, et al. Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study. Diabetes Obes Metab. 2016;18(12):1283\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1594_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","volume":"3","author":"SC Hung","year":"2015","unstructured":"Hung SC, Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015;3(8):605\u201314.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1594_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-55","volume":"15","author":"W Chen","year":"2014","unstructured":"Chen W, Abramowitz MK. Metabolic acidosis and the progression of chronic kidney disease. BMC Nephrol. 2014;15:55.","journal-title":"BMC Nephrol"},{"issue":"6","key":"1594_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2012","unstructured":"Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253\u201370.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"1594_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1463-1326.2006.00657.x","volume":"10","author":"S Runge","year":"2008","unstructured":"Runge S, Mayerle J, Warnke C, Robinson D, Roser M, Felix SB, et al. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab. 2008;10(1):91\u20133.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1594_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/cc11332","volume":"16","author":"A Protti","year":"2012","unstructured":"Protti A, Fortunato F, Monti M, Vecchio S, Gatti S, Comi GP, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care. 2012;16(3):R75.","journal-title":"Crit Care"},{"key":"1594_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.975912","volume":"13","author":"K Nabrdalik","year":"2022","unstructured":"Nabrdalik K, Skonieczna-Zydecka K, Irlik K, Hendel M, Kwiendacz H, Loniewski I, et al. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:975912.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"1594_CR30","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1210\/jc.2015-3754","volume":"101","author":"VR Aroda","year":"2016","unstructured":"Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"46","key":"1594_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017918","volume":"98","author":"J Kim","year":"2019","unstructured":"Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1594_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00592-009-0169-5","volume":"48","author":"GT Russo","year":"2011","unstructured":"Russo GT, Di Benedetto A, Magazzu D, Giandalia A, Giorda CB, Ientile R, et al. Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetol. 2011;48(2):95\u2013101.","journal-title":"Acta Diabetol"},{"issue":"12","key":"1594_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1507\/endocrj.EJ13-0332","volume":"60","author":"Y Sato","year":"2013","unstructured":"Sato Y, Ouchi K, Funase Y, Yamauchi K, Aizawa T. Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocr J. 2013;60(12):1275\u201380.","journal-title":"Endocr J"},{"key":"1594_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00753","volume":"9","author":"E Fontaine","year":"2018","unstructured":"Fontaine E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front Endocrinol (Lausanne). 2018;9:753.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1594_CR35","doi-asserted-by":"crossref","unstructured":"Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000 Jun 15;348 Pt 3(Pt 3):607-14.","DOI":"10.1042\/bj3480607"},{"issue":"2","key":"1594_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","volume":"65","author":"R DeFronzo","year":"2016","unstructured":"DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20\u20139.","journal-title":"Metabolism"},{"issue":"24","key":"1594_CR37","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.2014.15298","volume":"312","author":"SE Inzucchi","year":"2014","unstructured":"Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668\u201375.","journal-title":"JAMA"},{"issue":"Suppl 3","key":"1594_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.15749","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA. Optimizing metformin therapy in practice: tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes. Diabetes Obes Metab. 2024;26(Suppl 3):42\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1594_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.diabet.2016.03.008","volume":"42","author":"LE Chapman","year":"2016","unstructured":"Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B(12) deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2016;42(5):316\u201327.","journal-title":"Diabetes Metab"},{"issue":"9","key":"1594_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/1753-0407.12900","volume":"11","author":"W Yang","year":"2019","unstructured":"Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B(12) levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019;11(9):729\u201343.","journal-title":"J Diabetes"},{"issue":"10","key":"1594_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204420","volume":"13","author":"TJ Alharbi","year":"2018","unstructured":"Alharbi TJ, Tourkmani AM, Abdelhay O, Alkhashan HI, Al-Asmari AK, Bin Rsheed AM, et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. PLoS ONE. 2018;13(10):e0204420.","journal-title":"PLoS ONE"},{"issue":"1","key":"1594_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3945\/an.111.001370","volume":"3","author":"LH Allen","year":"2012","unstructured":"Allen LH. Vitamin B-12. Adv Nutr. 2012;3(1):54\u20135.","journal-title":"Adv Nutr"},{"key":"1594_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cca.2014.02.007","volume":"431","author":"S Mao","year":"2014","unstructured":"Mao S, Xiang W, Huang S, Zhang A. Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clin Chim Acta. 2014;431:206\u201310.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1594_CR44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12882-022-03045-6","volume":"23","author":"Z Shen","year":"2022","unstructured":"Shen Z, Zhang Z, Zhao W. Relationship between plasma homocysteine and chronic kidney disease in US patients with type 2 diabetes mellitus: a cross-sectional study. BMC Nephrol. 2022;23(1):419.","journal-title":"BMC Nephrol"},{"issue":"2","key":"1594_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000110876","volume":"28","author":"F Yi","year":"2008","unstructured":"Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol. 2008;28(2):254\u201364.","journal-title":"Am J Nephrol"},{"issue":"32","key":"1594_CR46","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.2174\/0929867321666140706142335","volume":"21","author":"S Pushpakumar","year":"2014","unstructured":"Pushpakumar S, Kundu S, Sen U. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem. 2014;21(32):3662\u201372.","journal-title":"Curr Med Chem"},{"issue":"6","key":"1594_CR47","doi-asserted-by":"publisher","first-page":"H2649","DOI":"10.1152\/ajpheart.00548.2005","volume":"289","author":"N Tyagi","year":"2005","unstructured":"Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol. 2005;289(6):H2649\u201356.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1594_CR48","doi-asserted-by":"publisher","first-page":"c2181","DOI":"10.1136\/bmj.c2181","volume":"340","author":"J de Jager","year":"2010","unstructured":"de Jager J, Kooy A, Lehert P, Wulffele MG, van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.","journal-title":"BMJ"},{"key":"1594_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-733","volume":"11","author":"F Marti","year":"2011","unstructured":"Marti F, Vollenweider P, Marques-Vidal PM, Mooser V, Waeber G, Paccaud F, et al. Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. BMC Public Health. 2011;11:733.","journal-title":"BMC Public Health"},{"issue":"1","key":"1594_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-018-0732-4","volume":"18","author":"GT Russo","year":"2018","unstructured":"Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A, Guida P, et al. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr. 2018;18(1):38.","journal-title":"BMC Geriatr"},{"key":"1594_CR51","doi-asserted-by":"crossref","unstructured":"Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006 Jun;55(6):1832-9.","DOI":"10.2337\/db05-1620"},{"issue":"7","key":"1594_CR52","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/nep.12468","volume":"20","author":"MK Yu","year":"2015","unstructured":"Yu MK, Katon W, Young BA. Associations between sex and incident chronic kidney disease in a prospective diabetic cohort. Nephrology (Carlton). 2015;20(7):451\u20138.","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"1594_CR53","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/dme.12478","volume":"31","author":"A de Hauteclocque","year":"2014","unstructured":"de Hauteclocque A, Ragot S, Slaoui Y, Gand E, Miot A, Sosner P, et al. The influence of sex on renal function decline in people with Type 2 diabetes. Diabet Med. 2014;31(9):1121\u20138.","journal-title":"Diabet Med"},{"issue":"6","key":"1594_CR54","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jdi.13040","volume":"10","author":"T Okamura","year":"2019","unstructured":"Okamura T, Ushigome E, Kitagawa N, Oyabu C, Tanaka T, Hasegawa G, et al. Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: the KAMOGAWA-HBP study. J Diabetes Investig. 2019;10(6):1543\u20139.","journal-title":"J Diabetes Investig"},{"key":"1594_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/IJGM.S255858","volume":"13","author":"F Hu","year":"2020","unstructured":"Hu F, Zhang T. Study on risk factors of diabetic nephropathy in obese patients with type 2 diabetes mellitus. Int J Gen Med. 2020;13:351\u201360.","journal-title":"Int J Gen Med"},{"key":"1594_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111454","volume":"138","author":"A Song","year":"2021","unstructured":"Song A, Zhang C, Meng X. Mechanism and application of metformin in kidney diseases: an update. Biomed Pharmacother. 2021;138:111454.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"1594_CR57","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1507\/endocrj.EJ14-0206","volume":"61","author":"S Furukawa","year":"2014","unstructured":"Furukawa S, Yamamoto S, Todo Y, Maruyama K, Miyake T, Ueda T, et al. Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus. Endocr J. 2014;61(10):1011\u20138.","journal-title":"Endocr J"},{"issue":"1","key":"1594_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2337\/dc11-1346","volume":"35","author":"G Zoppini","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99\u2013104.","journal-title":"Diabetes Care"},{"key":"1594_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122.","journal-title":"BMC Nephrol"},{"issue":"6","key":"1594_CR60","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71(6):851\u201365.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1594_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239\u201347.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1594_CR62","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1594_CR63","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"1594_CR64","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep"},{"issue":"8","key":"1594_CR65","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01594-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01594-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01594-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:02:11Z","timestamp":1793466131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01594-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01594-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki. This research involved a secondary analysis of data sourced from the NHIRD, which is overseen by the HWDC. The NHIRD assigns scrambled, random identification numbers to insured individuals to safeguard their privacy. Because all data included in this study were deidentified, the requirement for informed consent was waived. The study protocol was approved by the Central Regional Research Ethics Committee of China Medical University, Taichung, Taiwan (No. CRREC-109-011).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}